HC Wainwright reissued their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, Ratings reports.

Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...